Potential Cost Implications of Mandatory Non‐Medical Switching Policies for Biologics for Rheumatic Conditions and Inflammatory Bowel Disease in Canada-Reference-Cited by-同舟云学术

Potential Cost Implications of Mandatory Non‐Medical Switching Policies for Biologics for Rheumatic Conditions and Inflammatory Bowel Disease in Canada

Published:2020-10-03 Issue:3 Volume:109 Page:739-745
ISSN:0009-9236
Container-title:Clinical Pharmacology & Therapeutics
language:en
Short-container-title:Clin. Pharmacol. Ther.

Author:

Crosby Michael¹,Tadrous Mina¹²³,Gomes Tara¹³⁴⁵

Affiliation:

1. Leslie Dan Faculty of Pharmacy University of Toronto Toronto Ontario Canada

2. Women’s College Hospital Toronto Ontario Canada

3. ICES Toronto Ontario Canada

4. Li Ka Shing Knowledge Institute St. Michael’s Hospital Toronto Ontario Canada

5. Institute of Health Policy, Management, and Evaluation University of Toronto Toronto Ontario Canada

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cpt.2042

Reference29 articles.

1. Canadian Estimates of Health Care Utilization Costs for Rheumatoid Arthritis Patients With and Without Therapy With Biologic Agents

2. Canadian Institute for Health Information.Prescribed drug spending in Canada 2019: a focus on public drug programs (2019). Accessed March 5 2020.

3. Health Canada.Biosimilar biologic drugs in Canada: Fact Sheet (2019). Accessed March 6 2020.

4. Patented Medicine Prices Review Board.Biosimilars in Canada: current environment and future opportunity (2019). Accessed March 6 2020.

5. Government of British Columbia.Biosimilars initiative for patients. Accessed March 5 2020.

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. High Healthcare Costs in Childhood Inflammatory Bowel Disease: Development of a Prediction Model Using Linked Clinical and Health Administrative Data;Inflammatory Bowel Diseases;2024-07-19

2. Induction therapy with oral tacrolimus provides long-term benefit in thiopurine-naïve refractory ulcerative colitis patients despite low serum albumin levels;2023-12-14

3. The 2023 Impact of Inflammatory Bowel Disease in Canada: Direct Health System and Medication Costs;Journal of the Canadian Association of Gastroenterology;2023-09-01

4. Stairway to Heaven: Do head-to-head Trials Indicate a Need for Definite Criteria for Choosing Biologic Drugs in Rheumatoid Arthritis?;Current Rheumatology Reviews;2023-08-03

5. The cost of inflammatory bowel disease in high-income settings: a Lancet Gastroenterology & Hepatology Commission;The Lancet Gastroenterology & Hepatology;2023-05